JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.9, no.1, pp.22-26, 2008 (Journal Indexed in SCI)
Article / Article
Title of Journal :
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, high sensitive C-reactive protein, hypertension, plasma plasminogen activator inhibitor, tissue plasminogen activator, PLASMINOGEN-ACTIVATOR INHIBITOR-1, CORONARY-ARTERY-DISEASE, MYOCARDIAL-INFARCTION, CARDIOVASCULAR EVENTS, RANDOMIZED-TRIAL, HEART-FAILURE, HYPERTENSIVE PATIENTS, ENDOTHELIAL-CELLS, DOUBLE-BLIND, RISK
Introduction. Angiotensin-converting enzyme (ACE) inhibitors reduce cardiovascular events in patients with established vascular disease and heart failure (HF). ACE-inhibitors have important effects on fibrinolytic balance, which may be the underlying mechanism for a reduction in cardiovascular events. Although angiotensin receptor blockers (ARBs) offer greater tolerability than ACE-inhibitors, the major ARB trials have demonstrated a lack of reduction in myocardial infarction (MI) occurrence and mortality in contrast to ACE-inhibitors. In this study, we investigated the combined effects of ARBs and ACE-inhibitors on fibrinolytic and inflammatory parameters in patients with uncontrolled hypertension.